Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wasp venom protein
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Wasp venom protein refers to the complex mixture of allergenic proteins derived from the venom of wasps, primarily from the *Vespula* genus (yellow jackets), used in venom immunotherapy (VIT). This biologic agent is employed to desensitize individuals with IgE-mediated hypersensitivity to wasp stings, which can otherwise lead to life-threatening anaphylaxis. The mechanism of action involves the induction of peripheral T-cell tolerance, the promotion of regulatory T cells (Tregs) that secrete IL-10 and TGF-beta, and a shift in the antibody profile from allergen-specific IgE to protective IgG4. In the context of clinical research at the Universitair Medisch Centrum Groningen (UMCG), it has been studied in pilot trials evaluating accelerated or high-dose (100 µg) starting regimens to improve the efficiency and safety of the desensitization process.
- Other names
- wasp venom extractVespula species venom proteinVespula venom extractwasp venom immunotherapy
02
Targets
IL10 (Interleukin-10)BCR (Immunoglobulin G B Cell Receptor)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on wasp venom protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wasp venom protein.